Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Immix Biopharma Inc (NASDAQ:IMMX) announced preclinical data of its lead program, IMX-110.
- The data showed that IMX-110 produced a 50% response rate in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mouse study, surpassing the STS standard of care doxorubicin’s 0% response rate in the same mouse study.
- The responses were assessed by RECIST 1.1 criteria applied to mice, with progression assessed after one treatment cycle.
- The FDA has approved orphan drug designation for IMX-110 for soft tissue sarcoma. The FDA has already approved rare pediatric disease designation to IMX-110 for pediatric cancer, rhabdomyosarcoma.
- ImmixBio recently shared IMX-110 clinical data across multiple STS subtypes in several heavily pretreated patients demonstrating median progression-free survival (PFS) of 4 months.
- Zero drug-related severe adverse events and dose interruptions due to toxicity were observed.
- Price Action: IMMX shares are up 31.7% at $7.15 during the premarket session on the last check Wednesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!